cannabidiol and Bipolar-Disorder

cannabidiol has been researched along with Bipolar-Disorder* in 7 studies

Reviews

3 review(s) available for cannabidiol and Bipolar-Disorder

ArticleYear
    Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2020, Volume: 65, Issue:4

    To review the current evidence for efficacy of cannabidiol in the treatment of mood disorders.. We systematically searched PubMed, Embase, Web of Science, PsychInfo, Scielo, ClinicalTrials.gov , and The Cochrane Central Register of Controlled Trials for studies published up to July 31, 2019. The inclusion criteria were clinical trials, observational studies, or case reports evaluating the effect of pure cannabidiol or cannabidiol mixed with other cannabinoids on mood symptoms related to either mood disorders or other health conditions. The review was reported in accordance with guidelines from Preferred Reporting Items for Systematic reviews and Meta-Analyses protocol.. Of the 924 records initially yielded by the search, 16 were included in the final sample. Among them, six were clinical studies that used cannabidiol to treat other health conditions but assessed mood symptoms as an additional outcome. Similarly, four tested cannabidiol blended with Δ-9-tetrahydrocannabinol in the treatment of general health conditions and assessed affective symptoms as secondary outcomes. Two were case reports testing cannabidiol. Four studies were observational studies that evaluated the cannabidiol use and its clinical correlates. However, there were no clinical trials investigating the efficacy of cannabidiol, specifically in mood disorders or assessing affective symptoms as the primary outcome. Although some articles point in the direction of benefits of cannabidiol to treat depressive symptoms, the methodology varied in several aspects and the level of evidence is not enough to support its indication as a treatment for mood disorders.. There is a lack of evidence to recommend cannabidiol as a treatment for mood disorders. However, considering the preclinical and clinical evidence related to other diseases, cannabidiol might have a role as a treatment for mood disorders. Therefore, there is an urgent need for well-designed clinical trials investigating the efficacy of cannabidiol in mood disorders.

    Topics: Bipolar Disorder; Cannabidiol; Cannabinoid Receptor Modulators; Humans; Mood Disorders

2020
Endocannabinoid system dysfunction in mood and related disorders.
    Acta psychiatrica Scandinavica, 2011, Volume: 124, Issue:4

    The endocannabinoid (EC) system is widely distributed throughout the brain and modulates many functions. It is involved in mood and related disorders, and its activity may be modified by exogenous cannabinoids. This article examines the therapeutic potential of cannabinoids in psychiatric disorders.. An overview is presented of the literature focussed on the functions of the EC system, its dysfunction in mood disorders and the therapeutic potential of exogenous cannabinoids.. We propose (hypothesize) that the EC system, which is homoeostatic in cortical excitation and inhibition, is dysfunctional in mood and related disorders. Anandamide, tetrahydrocannabinol (THC) and cannabidiol (CBD) variously combine antidepressant, antipsychotic, anxiolytic, analgesic, anticonvulsant actions, suggesting a therapeutic potential in mood and related disorders. Currently, cannabinoids find a role in pain control. Post mortem and other studies report EC system abnormalities in depression, schizophrenia and suicide. Abnormalities in the cannabinoid-1 receptor (CNR1) gene that codes for cannabinoid-1 (CB1) receptors are reported in psychiatric disorders. However, efficacy trials of cannabinoids in psychiatric disorders are limited but offer some encouragement.. Research is needed to elucidate the role of the EC system in psychiatric disorders and for clinical trials with THC, CBD and synthetic cannabinoids to assess their therapeutic potential.

    Topics: Anxiety; Bipolar Disorder; Cannabidiol; Cannabinoid Receptor Modulators; Cannabinoids; Cerebral Cortex; Depression; Dronabinol; Electroencephalography; Endocannabinoids; Humans; Mood Disorders; Pain; Receptors, Cannabinoid; Schizophrenia; Suicide

2011
Cannabinoids in bipolar affective disorder: a review and discussion of their therapeutic potential.
    Journal of psychopharmacology (Oxford, England), 2005, Volume: 19, Issue:3

    Bipolar affective disorder is often poorly controlled by prescribed drugs. Cannabis use is common in patients with this disorder and anecdotal reports suggest that some patients take it to alleviate symptoms of both mania and depression. We undertook a literature review of cannabis use by patients with bipolar disorder and of the neuropharmacological properties of cannabinoids suggesting possible therapeutic effects in this condition. No systematic studies of cannabinoids in bipolar disorder were found to exist, although some patients claim that cannabis relieves symptoms of mania and/or depression. The cannabinoids Delta(9)-tetrahydrocannabinol (THC) and cannabidiol (CBD) may exert sedative, hypnotic, anxiolytic, antidepressant, antipsychotic and anticonvulsant effects. Pure synthetic cannabinoids, such as dronabinol and nabilone and specific plant extracts containing THC, CBD, or a mixture of the two in known concentrations, are available and can be delivered sublingually. Controlled trials of these cannabinoids as adjunctive medication in bipolar disorder are now indicated.

    Topics: Arachidonic Acids; Bipolar Disorder; Cannabidiol; Cannabinoids; Dronabinol; Endocannabinoids; Humans; Polyunsaturated Alkamides; Receptor, Cannabinoid, CB1

2005

Other Studies

4 other study(ies) available for cannabidiol and Bipolar-Disorder

ArticleYear
Cannabidiol for Mood Disorders: A Call for More Research.
    Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2021, Volume: 66, Issue:2

    Topics: Bipolar Disorder; Cannabidiol; Depressive Disorder, Major; Humans; Mood Disorders

2021
Effects of cannabidiol on amphetamine-induced oxidative stress generation in an animal model of mania.
    Journal of psychopharmacology (Oxford, England), 2011, Volume: 25, Issue:2

    Cannabidiol (CBD), a Cannabis sativa constituent, may present a pharmacological profile similar to mood stabilizing drugs, in addition to anti-oxidative and neuroprotective properties. The present study aims to directly investigate the effects of CBD in an animal model of mania induced by D-amphetamine (D-AMPH). In the first model (reversal treatment), rats received saline or D-AMPH (2 mg/kg) once daily intraperitoneal (i.p.) for 14 days, and from the 8th to the 14th day, they were treated with saline or CBD (15, 30 or 60 mg/kg) i.p. twice a day. In the second model (prevention treatment), rats were pretreated with saline or CBD (15, 30, or 60 mg/kg) regime i.p. twice a day, and from the 8th to the 14th day, they also received saline or D-AMPH i.p. once daily. In the hippocampus CBD (15 mg/kg) reversed the d-AMPH-induced damage and increased (30 mg/kg) brain-derived neurotrophic factor (BDNF) expression. In the second experiment, CBD (30 or 60 mg/kg) prevented the D-AMPH-induced formation of carbonyl group in the prefrontal cortex. In the hippocampus and striatum the D-AMPH-induced damage was prevented by CBD (15, 30 or 60 mg/kg). At both treatments CBD did not present any effect against d-AMPH-induced hyperactivity. In conclusion, we could not observe effects on locomotion, but CBD protect against d-AMPH-induced oxidative protein damage and increased BDNF levels in the reversal model and these effects vary depending on the brain regions evaluated and doses of CBD administered.

    Topics: Amphetamine; Animals; Antimanic Agents; Bipolar Disorder; Brain-Derived Neurotrophic Factor; Cannabidiol; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Hippocampus; Hyperkinesis; Male; Motor Activity; Oxidative Stress; Prefrontal Cortex; Protein Carbonylation; Rats; Rats, Wistar

2011
Cannabidiol was ineffective for manic episode of bipolar affective disorder.
    Journal of psychopharmacology (Oxford, England), 2010, Volume: 24, Issue:1

    The pharmacological profile of cannabidiol (CBD) has several characteristics in common with drugs known to benefit bipolar affective disorder (BAD), leading to the hypothesis that CBD may have therapeutic properties in BAD. Therefore, the aim of the present report was to directly investigate for the first time the efficacy and safety of CBD in two patients with BAD. Both patients met DSM IV criteria for bipolar I disorder experiencing a manic episode without comorbid conditions. This was an inpatient study, and the efficacy, tolerability and side effects were assessed. Both patients received placebo for the initial 5 days and CBD from the 6th to 30th day (initial oral dose of 600 mg reaching 1200 mg/ day). From the 6th to the 20th day, the first patient (a 34-year-old woman) received adjunctive olanzapine (oral dose of 10-15 mg). On day 31, CBD treatment was discontinued and replaced by placebo for 5 days. The first patient showed symptoms improvement while on olanzapine plus CBD, but showed no additional improvement during CBD monotherapy. The second patient (a 36-year-old woman) had no symptoms improvement with any dose of CBD during the trial. Both patients tolerated CBD very well and no side-effects were reported. These preliminary data suggest that CBD may not be effective for the manic episode of BAD.

    Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Cannabidiol; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Olanzapine; Single-Blind Method; Treatment Outcome

2010
Potential therapeutical effects of cannabidiol in children with pharmacoresistant epilepsy.
    Medical hypotheses, 2007, Volume: 68, Issue:4

    Topics: Adolescent; Aerosols; Anticonvulsants; Bipolar Disorder; Cannabidiol; Child; Drug Resistance; Epilepsy; Humans; Models, Biological

2007